Page last updated: 2024-11-12

uk 453,061

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

UK 453,061: a reverse transcriptase inhibitor/anti-HIV agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16739244
CHEMBL ID571987
CHEBI ID177465
SCHEMBL ID508446
MeSH IDM0524491

Synonyms (45)

Synonym
lersivirine (uk-453061)
5-[3,5-diethyl-1-(2-hydroxyethyl)pyrazol-4-yl]oxybenzene-1,3-dicarbonitrile
CHEBI:177465
473921-12-9
lersivirine
uk-453061
5-{3,5-diethyl-1-(2hydroxyethyl)-1h-pyrazol-4-yl]isophthalonitrile
uk-453,061
zze ,
5-{[3,5-diethyl-1-(2-hydroxyethyl)-1h-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile
CHEMBL571987
3-cyano-5-[[3,5-diethyl-1-(2-hydroxyethyl)-1h-pyrazol-4-yl]oxy]benzonitrile
D09634
lersivirine (usan/inn)
r3zgc15a9a ,
lersivirine [usan:inn]
unii-r3zgc15a9a
5-((3,5-diethyl-1-(2-hydroxyethyl)-1h-pyrazol-4-yl)oxy)benzene-1,3-dicarbonitrile
uk 453,061
1,3-benzenedicarbonitrile, 5-((3,5-diethyl-1-(2-hydroxyethyl)-1h-pyrazol-4-yl)oxy)-
HY-14267
CS-1191
S8055
SCHEMBL508446
2WON
lersivirine [usan]
lersivirine [inn]
lersivirine [who-dd]
DTXSID0057881
5-((3,5-diethyl-1-(2-hydroxyethyl)-1h-pyrazol-4-yl)oxy)isophthalonitrile
uk 453061
EX-A165
AKOS030526818
bdbm50483552
mfcd16619314
NCGC00378968-01
lersivirineuk 453061
DB11649
FT-0745075
BCP08443
BS-17083
SB17095
lersivirine(uk 453061)
Q27287760
A872162

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The requirements for safe testing of pharmaceuticals in humans places substantial emphasis on the translation of safety testing performed in animals to man."( Species differences in the multiple-dose pharmacokinetics of the non-nucleoside reverse transcriptase inhibitor (NNRTI) UK-453,061 in animals and man: implications for safety considerations.
Davis, J; Gardner, IB; Houle, C; Walker, DK; Webster, R, 2009
)
0.35
" The most commonly reported treatment-emergent adverse events were headache, fatigue and nausea."( Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients.
Davis, J; Fätkenheuer, G; Hackman, F; Jenkins, TM; Layton, G; McFadyen, L; Plettenburg, A; Staszewski, S, 2009
)
0.35
" Lersivirine was safe and well tolerated."( Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients.
Davis, J; Fätkenheuer, G; Hackman, F; Jenkins, TM; Layton, G; McFadyen, L; Plettenburg, A; Staszewski, S, 2009
)
0.35
" Safety and tolerability were assessed throughout the study by continuous collection of adverse events (AEs), including adverse drug reactions, illnesses with onset during the study, exacerbation of previous illnesses, and clinically significant changes in physical examination findings."( Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers.
Choo, H; Davis, J; Goodrich, J; Hackman, F; Langdon, G; Lewis, D; Ndongo, MN; Tawadrous, M, 2010
)
0.36
" Overall incidences of all-causality treatment-related or grade 3/4 adverse events (AEs) or AE-related discontinuations were lower with lersivirine than with efavirenz, and serious AEs occurred at similar rates across treatment groups."( Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial.
Cooper, DA; Craig, C; Goodrich, J; Kaplan, R; Lazzarin, A; Mori, J; Pozniak, A; Pulik, P; Tawadrous, M; Valdez, H; Vernazza, P; Wang, C; Weil, E, 2013
)
0.39
" Lersivirine and etravirine were generally safe and well-tolerated."( Efficacy and safety of lersivirine versus etravirine for the treatment of HIV-1 infection in patients with prior non-nucleoside reverse transcriptase inhibitor (NNRTI) use and evidence of NNRTI resistance: a randomized phase 2B trial.
Craig, C; DeJesus, E; Fätkenheuer, G; Heera, J; Jones, J; Orrell, C; Tawadrous, M; Wang, C,
)
0.13

Pharmacokinetics

ExcerptReferenceRelevance
" Four studies evaluated the pharmacokinetic (PK) interactions between lersivirine and various HIV-1 protease inhibitors."( The pharmacokinetics of lersivirine (UK-453,061) and HIV-1 protease inhibitor coadministration in healthy subjects.
Choo, HW; Davis, J; Labadie, RR; Langdon, G; Layton, G; Ndongo, MN; Vourvahis, M, 2012
)
0.38
" PK data included the area under the plasma concentration-time profile from time zero to the end of the dosing interval (AUC24), maximum plasma concentration (Cmax), minimum plasma concentration (Cmin, C24, or Ctrough), and time to Cmax (Tmax)."( The pharmacokinetics of lersivirine (UK-453,061) and HIV-1 protease inhibitor coadministration in healthy subjects.
Choo, HW; Davis, J; Labadie, RR; Langdon, G; Layton, G; Ndongo, MN; Vourvahis, M, 2012
)
0.38
"To investigate pharmacokinetic interactions associated with coadministration of lersivirine with zidovudine, tenofovir disoproxil fumarate (DF)/emtricitabine (Truvada(®)) or abacavir/lamivudine (Epzicom(®)/Kivexa(®))."( Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
Choo, HW; Davis, J; Fang, J; Hansson, AG; Langdon, G; Layton, G; Tawadrous, M; Vourvahis, M, 2013
)
0.39
" Pharmacokinetic parameters were calculated by standard non-compartmental methods."( Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
Choo, HW; Davis, J; Fang, J; Hansson, AG; Langdon, G; Layton, G; Tawadrous, M; Vourvahis, M, 2013
)
0.39

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" This study demonstrates the utility of using in silico PBPK approaches to make predictions of human pharmacokinetics before dosing for the first time in humans."( Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man.
Allan, G; Davis, J; Dickins, M; Gardner, I; Jenkins, T; Jones, H; Webster, R; Westgate, H, 2008
)
0.35
"To investigate the effects on viral load and assess dose-response relationships, pharmacokinetics, safety and tolerability of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, in asymptomatic HIV-1-infected patients."( Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients.
Davis, J; Fätkenheuer, G; Hackman, F; Jenkins, TM; Layton, G; McFadyen, L; Plettenburg, A; Staszewski, S, 2009
)
0.35
"Lersivirine appeared to be well tolerated after 28 days of continuous dosing in this small, selected group of young, healthy male volunteers."( Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers.
Choo, H; Davis, J; Goodrich, J; Hackman, F; Langdon, G; Lewis, D; Ndongo, MN; Tawadrous, M, 2010
)
0.36
" Minor, clinically nonsignificant effects on the pharmacokinetics of raltegravir coadministered with lersivirine were observed at steady state for raltegravir, with estimated mean changes of -15%, -29%, and +25% in the area under the concentration-time profile from time zero to the end of the dosing interval (AUC(tau)), maximum plasma concentration (C(max)), and concentration observed 12 h postdose (C(12)), respectively."( Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects.
Banerjee, S; Davis, J; Labadie, RR; Langdon, G; Layton, G; Ndongo, MN; Vourvahis, M, 2012
)
0.38
" The first 2 days of dosing for the high-dose group were done at 250 mg/kg to allow induction of hepatic metabolizing enzymes, after which the dose was increased to 500 mg/kg/day."( Developmental toxicity study of lersivirine in mice.
Bowman, CJ; Campion, SN; Cappon, GD; Chmielewski, G; Finch, GL; Hurtt, ME; Lewis, EM, 2012
)
0.38
" Control rabbits were administered vehicle following the same dosing regimen from GDs 8 to 13."( Developmental toxicity of lersivirine in rabbits when administered throughout organogenesis and when limited to sensitive windows of axial skeletal development.
Bowman, CJ; Campion, SN; Cappon, GD; Finch, GL; Harrison, A; Hurtt, ME, 2012
)
0.38
" PK data included the area under the plasma concentration-time profile from time zero to the end of the dosing interval (AUC24), maximum plasma concentration (Cmax), minimum plasma concentration (Cmin, C24, or Ctrough), and time to Cmax (Tmax)."( The pharmacokinetics of lersivirine (UK-453,061) and HIV-1 protease inhibitor coadministration in healthy subjects.
Choo, HW; Davis, J; Labadie, RR; Langdon, G; Layton, G; Ndongo, MN; Vourvahis, M, 2012
)
0.38
" Healthy subjects were co-administered (1) single dose midazolam, a prototypical CYP3A4 substrate, followed by 14 days of lersivirine twice daily with single dose midazolam on the final day of lersivirine dosing or (2) 10 days of once-daily (QD) lersivirine and QD oral contraceptives (OCs; ethinylestradiol and levonorgestrel), substrates for CYP3A4, UGT2B7, and/or P-glycoprotein."( The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects.
Chong, CL; Davis, J; Langdon, G; Layton, G; Ndongo, MN; Vourvahis, M, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency23.91850.01237.983543.2770AID1645841
GVesicular stomatitis virusPotency26.83700.01238.964839.8107AID1645842
Interferon betaHomo sapiens (human)Potency26.83700.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency26.83700.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency26.83700.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency26.83700.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)0.16650.00011.076810.0000AID583849; AID583863
Reverse transcriptase/RNaseH Human immunodeficiency virus 1Ki0.11700.00031.552310.0000AID583851
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HIV-1 REVERSE TRANSCRIPTASEHuman immunodeficiency virus 1Kd0.62400.62400.62400.6240AID977611
Reverse transcriptase/RNaseH Human immunodeficiency virus 1Kd0.62400.00062.40599.8000AID583850
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (45)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (185)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID584260Inhibition of human L-type calcium channel diltiazem binding site at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID446250Volume of distribution in rat at 2 mg/kg, iv2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID584076Ratio of EC50 for wild type HIV1 NL4-3 to EC50 for HIV1 NL4-3 harboring reverse transcriptase L234I mutant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID446238Antiviral activity against HIV RF infected in human SupT1 cells2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID523086AUC (infinity) in healthy human plasma at 750 mg coadministered with 20 ml of antacid by HPLC-tandem mass spectrometry method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine.
AID1163253Trypanocidal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 SV2 cells assessed as parasite growth inhibition after 168 hrs by beta-galactosidase assay2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID583872Inhibition of HIV1 histidine-tagged reverse transcriptase Y181I mutant activity by primer extension assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584031Inhibition of HIV1 histidine-tagged reverse transcriptase P236L mutant activity by primer extension assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID523089Tmax in healthy human plasma at 750 mg coadministered with 20 ml of antacid by HPLC-tandem mass spectrometry method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine.
AID584254Inhibition of human neuronal nicotinic acid receptor at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID446239Cytotoxicity against human SupT1 cells2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID584030Inhibition of HIV1 histidine-tagged reverse transcriptase L234I mutant activity by primer extension assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584047Ratio of IC50 for HIV1 reverse transcriptase Y181C, Y188C mutant to IC50 for wild type HIV1 reverse transcriptase2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID523099Toxicity in healthy human assessed as serious adverse events at 750 mg coadministered with 20 ml of antacid2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine.
AID584237Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase V108I mutant derived from 17 days viral passages with lersivirine infected in human SupT1 cells assessed as inhibition of viral replication after 21 days relative to wild type HIV1 NL4-2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584064Ratio of EC50 for wild type HIV1 NL4-3 to EC50 for HIV1 NL4-3 harboring reverse transcriptase V106A mutant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID523094Tmax in healthy human plasma at 750 mg by HPLC-tandem mass spectrometry method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine.
AID523101Toxicity in healthy human assessed as gastrointestinal tract related toxicity at 750 mg coadministered with 20 ml of antacid2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine.
AID584040Ratio of IC50 for HIV1 reverse transcriptase M184V mutant to IC50 for wild type HIV1 reverse transcriptase2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID583860Ratio of CC30 for human PBL cells to EC90 for HIV12010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584043Ratio of IC50 for HIV1 reverse transcriptase E233V mutant to IC50 for wild type HIV1 reverse transcriptase2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID446251Half life in rat at 2 mg/kg, iv2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID635196Antiviral activity against Human immunodeficiency virus expressing RT K103N/Y181C double mutant infected in human MT4 cells by p24 antigen assay in the presence of 50% normal human serum2011Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24
Design and synthesis of pyridone inhibitors of non-nucleoside reverse transcriptase.
AID584236Ratio of EC50 for wild type HIV1 NL4-3 to EC50 for HIV1 NL4-3 harboring reverse transcriptase Y181C, V179V/D mutant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584060Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase Y181C, Y188C mutant infected in human HeLaP4 cells assessed as inhibition of viral replication after 5 days by beta-galactosidase reporter assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584078Ratio of EC50 for wild type HIV1 NL4-3 to EC50 for HIV1 NL4-3 harboring reverse transcriptase Y181I, Y188L mutant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584055Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase Y188C mutant infected in human HeLaP4 cells assessed as inhibition of viral replication after 5 days by beta-galactosidase reporter assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID523091AUC (infinity) in healthy human plasma at 750 mg by HPLC-tandem mass spectrometry method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine.
AID1163230Antitrypanocidal activity against suramin-sensitive Trypanosoma brucei brucei Squib427 assessed as reduction in parasite growth after 72 hrs2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID584038Ratio of IC50 for HIV1 reverse transcriptase Y181C mutant to IC50 for wild type HIV1 reverse transcriptase2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584048Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase K101E mutant infected in human HeLaP4 cells assessed as inhibition of viral replication after 5 days by beta-galactosidase reporter assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID525728Half life in rat2010Journal of medicinal chemistry, Nov-25, Volume: 53, Issue:22
Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore.
AID584240Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase Y181C, V108V/I, V179V/D mutant derived from 17 days viral passages with lersivirine infected in human SupT1 cells assessed as inhibition of viral replication after 21 days relative to w2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584068Ratio of EC50 for wild type HIV1 NL4-3 to EC50 for HIV1 NL4-3 harboring reverse transcriptase Y181I mutant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID583874Inhibition of HIV1 histidine-tagged reverse transcriptase Y188C mutant activity by primer extension assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID583853Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.05 multiplicities of infection after 6 days2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID1163231Antitrypanocidal activity against suramin-sensitive Trypanosoma brucei rhodesiense STIB-900 assessed as reduction in parasite growth after 72 hrs2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID523098Toxicity in healthy human assessed as serious adverse events at 750 mg2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine.
AID583845Antiviral activity against wild type HIV1 NL4-3 infected in human HeLaP4 cells assessed as inhibition of viral replication after 5 days by beta-galactosidase reporter assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584253Inhibition of human non-selective muscarinic receptor at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584258Inhibition of human 5-HT2A receptor at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID446409Fold resistance, ratio of IC50 for HIV reverse transcriptase with L100I mutant to IC50 for HIV wild type reverse transcriptase2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID584065Ratio of EC50 for wild type HIV1 NL4-3 to EC50 for HIV1 NL4-3 harboring reverse transcriptase V108I mutant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID1163254Antileishmanial activity against Leishmania infantum MHOM/MA (BE)/67 infected in primary peritoneal mouse macrophages assessed as reduction in parasite burdun2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID584075Ratio of EC50 for wild type HIV1 NL4-3 to EC50 for HIV1 NL4-3 harboring reverse transcriptase Y181C, Y188C mutant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID446243Displacement of [3H]dofetilide from human ERG expressed in HEK293 cells at 25 uM2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID584072Ratio of EC50 for wild type HIV1 NL4-3 to EC50 for HIV1 NL4-3 harboring reverse transcriptase E233V mutant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584251Inhibition of human NMDA receptor at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584062Ratio of EC50 for wild type HIV1 NL4-3 to EC50 for HIV1 NL4-3 harboring reverse transcriptase L100I mutant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584265Inhibition of human MAO-B at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584039Ratio of IC50 for HIV1 reverse transcriptase Y181I mutant to IC50 for wild type HIV1 reverse transcriptase2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID523100Toxicity in healthy human assessed as gastrointestinal tract related toxicity at 750 mg2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine.
AID584069Ratio of EC50 for wild type HIV1 NL4-3 to EC50 for HIV1 NL4-3 harboring reverse transcriptase M184V mutant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID701091Antiviral activity against HIV1 infected in human assessed as log reduction in viral load at 500 mg administered QD for 7 days measured on day 8 relative to placebo-control2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms.
AID584249Inhibition of human dopamine D1 receptor at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584247Inhibition of human AT1 receptor at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584049Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase V106A mutant infected in human HeLaP4 cells assessed as inhibition of viral replication after 5 days by beta-galactosidase reporter assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID525725Inhibition of HIV RT2010Journal of medicinal chemistry, Nov-25, Volume: 53, Issue:22
Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore.
AID584256Inhibition of human 5-HT1A receptor at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584059Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase V106A, Y181C mutant infected in human HeLaP4 cells assessed as inhibition of viral replication after 5 days by beta-galactosidase reporter assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID446240Metabolic stability in human liver microsomes assessed as half life2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID584046Ratio of IC50 for HIV1 reverse transcriptase F227C mutant to IC50 for wild type HIV1 reverse transcriptase2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584079Ratio of EC50 for wild type HIV1 NL4-3 to EC50 for HIV1 NL4-3 harboring reverse transcriptase V106A, F227L mutant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID583850Binding affinity to recombinant HIV1 reverse transcriptase by isothermal calorimetry2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID583857Cytotoxicity against human HeLaP4 cells at 200 uM by aqueous nonradioactive cell proliferation assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID583870Inhibition of HIV1 histidine-tagged reverse transcriptase E138K mutant activity by primer extension assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID523097Toxicity in healthy human assessed as death at 750 mg coadministered with 20 ml of antacid2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine.
AID584266Inhibition of human tyrosine hydroxylase at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584054Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase M184V mutant infected in human HeLaP4 cells assessed as inhibition of viral replication after 5 days by beta-galactosidase reporter assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID525726Half life in human liver microsomes2010Journal of medicinal chemistry, Nov-25, Volume: 53, Issue:22
Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore.
AID446258Fold resistance, ratio of IC50 for HIV reverse transcriptase with P236L mutant to IC50 for HIV wild type reverse transcriptase2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID583862Binding affinity to HIV1 HXB2 reverse transcriptase K103N mutant by protein X-ray crystallography analysis2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584248Inhibition of human central benzodiazepine receptor at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID583846Ratio of IC50 for HIV1 reverse transcriptase V106A, F227L mutant to IC50 for wild type HIV1 reverse transcriptase2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584070Ratio of EC50 for wild type HIV1 NL4-3 to EC50 for HIV1 NL4-3 harboring reverse transcriptase Y188C mutant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID635136Antiviral activity against Human immunodeficiency virus expressing wild type RT infected in human MT4 cells by p24 antigen assay in the presence of 50% normal human serum2011Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24
Design and synthesis of pyridone inhibitors of non-nucleoside reverse transcriptase.
AID583873Inhibition of HIV1 histidine-tagged reverse transcriptase M184V mutant activity by primer extension assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID523096Toxicity in healthy human assessed as death at 750 mg2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine.
AID1163234Cytotoxicity against human TZM-bl cells assessed as cell viability after 48 hrs by WST1 assay2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID701090Antiviral activity against HIV1 infected in human assessed as log reduction in viral load at 750 mg administered QD for 7 days measured on day 8 relative to placebo-control2012Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8
Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms.
AID584082Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase L100I, K103Q, H221H/Y mutant infected in human SupT1 cells derived from 11 viral passages with efavirenz assessed as inhibition of viral replication after 21 days relative to drug sensi2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID446252Fold resistance, ratio of IC50 for HIV reverse transcriptase with K103N mutant to IC50 for HIV wild type reverse transcriptase2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID523093Cmax in healthy human plasma at 750 mg after 24 hrs by HPLC-tandem mass spectrometry method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine.
AID446237Distribution coefficient, log D of the compound2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID584264Inhibition of human MAO-A at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID523090Half life in healthy human plasma at 750 mg coadministered with 20 ml of antacid by HPLC-tandem mass spectrometry method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine.
AID584051Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase E138K mutant infected in human HeLaP4 cells assessed as inhibition of viral replication after 5 days by beta-galactosidase reporter assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584041Ratio of IC50 for HIV1 reverse transcriptase Y188C mutant to IC50 for wild type HIV1 reverse transcriptase2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID583847Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase V108I, E138K mutant infected in human SupT1 cells derived from 9 viral passages with lersivirine assessed as inhibition of viral replication after 21 days relative to drug sensitive HIV2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID583866Inhibition of HIV1 histidine-tagged reverse transcriptase K101E mutant activity by primer extension assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584263Inhibition of human acetylcholinesterase at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584077Ratio of EC50 for wild type HIV1 NL4-3 to EC50 for HIV1 NL4-3 harboring reverse transcriptase F227C mutant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID583855Inhibition of human DNA polymerase beta2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584061Ratio of EC50 for wild type HIV1 NL4-3 to EC50 for HIV1 NL4-3 harboring reverse transcriptase K103N mutant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID583843Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase L100I mutant infected in human HeLaP4 cells assessed as inhibition of viral replication after 5 days by beta-galactosidase reporter assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584081Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase V108I, H221Y, F227F/L, M230M/I mutant infected in human SupT1 cells derived from 11 viral passages with lersivirine assessed as inhibition of viral replication after 21 days relative to2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584053Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase Y181I mutant infected in human HeLaP4 cells assessed as inhibition of viral replication after 5 days by beta-galactosidase reporter assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584255Inhibition of human non-selective opioid receptor at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID583871Inhibition of HIV1 histidine-tagged reverse transcriptase Y181C mutant activity by primer extension assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID525727Clearance in rat2010Journal of medicinal chemistry, Nov-25, Volume: 53, Issue:22
Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore.
AID523092Plasma concentration in healthy human plasma at 750 mg by HPLC-tandem mass spectrometry method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine.
AID584073Ratio of EC50 for wild type HIV1 NL4-3 to EC50 for HIV1 NL4-3 harboring reverse transcriptase P236L mutant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID1163255Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 infected in human O positive erythrocyte assessed as reduction in parasitemia after 72 hrs2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID583859Ratio of CC30 for human HeLaP4 cells to EC90 for HIV12010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID446257Fold resistance, ratio of IC50 for HIV reverse transcriptase with K101E mutant to IC50 for HIV wild type reverse transcriptase2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID583844Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase K103N mutant infected in human HeLaP4 cells assessed as inhibition of viral replication after 5 days by beta-galactosidase reporter assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID446410Fold resistance, ratio of IC50 for HIV reverse transcriptase with L234I mutant to IC50 for HIV wild type reverse transcriptase2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID583848Antiviral activity against HIV1 NL4-3 infected in human SupT1 cells derived from 11 viral passages assessed as inhibition of viral replication after 21 days relative to drug sensitive HIV1 NL4-32010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID583849Inhibition of HIV1 reverse transcriptase activity by primer extension assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584243Inhibition of human adrenergic alpha1 receptor at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584084Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase Y181C mutant infected in human SupT1 cells assessed as inhibition of viral replication after 21 days relative to wild type HIV1 NL4-32010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID635197Plasma protein binding in human2011Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24
Design and synthesis of pyridone inhibitors of non-nucleoside reverse transcriptase.
AID583867Inhibition of HIV1 histidine-tagged reverse transcriptase K103N mutant activity by primer extension assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584037Ratio of IC50 for HIV1 reverse transcriptase E138K mutant to IC50 for wild type HIV1 reverse transcriptase2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584252Inhibition of human histamine H1 receptor at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID583861Noncovalent binding affinity to wild type recombinant HIV1 HXB2 reverse transcriptase by protein X-ray crystallography analysis2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584032Ratio of IC50 for HIV1 reverse transcriptase L100I mutant to IC50 for wild type HIV1 reverse transcriptase2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID583851Mixed non-competitive inhibition of HIV1 reverse transcriptase activity2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID446254Fold resistance, ratio of IC50 for HIV reverse transcriptase with F227L mutant to IC50 for HIV wild type reverse transcriptase2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID584083Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase K103N mutant infected in human SupT1 cells assessed as inhibition of viral replication after 21 days relative to wild type HIV1 NL4-32010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID523088Cmax in healthy human plasma at 750 mg after 24 hrs coadministered with 20 ml of antacid by HPLC-tandem mass spectrometry method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine.
AID583854Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.5 multiplicities of infection after 6 days2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584239Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase Y181C, V179V/D mutant derived from 17 days viral passages with lersivirine infected in human SupT1 cells assessed as inhibition of viral replication after 21 days relative to wild type 2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID583858Cytotoxicity against human PBMC cells by aqueous nonradioactive cell proliferation assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID583868Inhibition of HIV1 histidine-tagged reverse transcriptase V106A mutant activity by primer extension assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584033Ratio of IC50 for HIV1 reverse transcriptase K101E mutant to IC50 for wild type HIV1 reverse transcriptase2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584074Ratio of EC50 for wild type HIV1 NL4-3 to EC50 for HIV1 NL4-3 harboring reverse transcriptase V106A, Y181C mutant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584029Inhibition of HIV1 histidine-tagged reverse transcriptase E233V mutant activity by primer extension assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584058Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase P236L mutant infected in human HeLaP4 cells assessed as inhibition of viral replication after 5 days by beta-galactosidase reporter assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584063Ratio of EC50 for wild type HIV1 NL4-3 to EC50 for HIV1 NL4-3 harboring reverse transcriptase K101E mutant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584080Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase V108I, E138K, F227F/L mutant infected in human SupT1 cells derived from 11 viral passages with lersivirine assessed as inhibition of viral replication after 21 days relative to drug sen2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID635195Antiviral activity against Human immunodeficiency virus expressing RT Y181C mutant infected in human MT4 cells by p24 antigen assay in the presence of 50% normal human serum2011Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24
Design and synthesis of pyridone inhibitors of non-nucleoside reverse transcriptase.
AID583869Inhibition of HIV1 histidine-tagged reverse transcriptase V108I mutant activity by primer extension assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID583864Ratio of IC50 for HIV1 HXB2 reverse transcriptase K103N mutant to IC50 for wild type HIV1 reverse transcriptase2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID446408Fold resistance, ratio of IC50 for HIV reverse transcriptase with V108I mutant to IC50 for HIV wild type reverse transcriptase2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID584056Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase F227L mutant infected in human HeLaP4 cells assessed as inhibition of viral replication after 5 days by beta-galactosidase reporter assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID446256Fold resistance, ratio of IC50 for HIV reverse transcriptase with Y188C mutant to IC50 for HIV wild type reverse transcriptase2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID584035Ratio of IC50 for HIV1 reverse transcriptase V106A mutant to IC50 for wild type HIV1 reverse transcriptase2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584242Inhibition of human adenosine A1 receptor at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID583865Inhibition of HIV1 histidine-tagged reverse transcriptase L100I mutant activity by primer extension assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584250Inhibition of human dopamine D2 receptor at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID583863Inhibition of HIV1 HXB2 reverse transcriptase K103N mutant activity by primer extension assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584259Inhibition of human L-type calcium channel dihydropyridine binding site at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584262Inhibition of human Phosphodiesterase 3 at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584052Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase Y181C mutant infected in human HeLaP4 cells assessed as inhibition of viral replication after 5 days by beta-galactosidase reporter assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584261Inhibition of human L-type calcium channel verapamil binding site at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID446255Fold resistance, ratio of IC50 for HIV reverse transcriptase with V106A mutant to IC50 for HIV wild type reverse transcriptase2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID635194Antiviral activity against Human immunodeficiency virus expressing RT K103N mutant infected in human MT4 cells by p24 antigen assay in the presence of 50% normal human serum2011Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24
Design and synthesis of pyridone inhibitors of non-nucleoside reverse transcriptase.
AID584257Inhibition of human 5-HT1B receptor at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID446236Inhibition of HIV reverse transcriptase2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID584042Ratio of IC50 for HIV1 reverse transcriptase F227L mutant to IC50 for wild type HIV1 reverse transcriptase2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584267Inhibition of human Na+/ K+ ATPase at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584245Inhibition of human adrenergic beta1 receptor at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID635128Cytotoxicity against human MT4 cells2011Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24
Design and synthesis of pyridone inhibitors of non-nucleoside reverse transcriptase.
AID584028Inhibition of HIV1 histidine-tagged reverse transcriptase F227L mutant activity by primer extension assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584246Inhibition of human adrenergic beta2 receptor at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584244Inhibition of human adrenergic alpha2 receptor at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584238Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase K103N, V108V/I mutant derived from 10 days viral passages with lersivirine infected in human SupT1 cells assessed as inhibition of viral replication after 21 days relative to wild type 2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584235Ratio of EC50 for wild type HIV1 NL4-3 to EC50 for HIV1 NL4-3 harboring reverse transcriptase Y181C, V108V/I, V179V/D mutant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584066Ratio of EC50 for wild type HIV1 NL4-3 to EC50 for HIV1 NL4-3 harboring reverse transcriptase E138K mutant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID523087Plasma concentration in healthy human plasma at 750 mg coadministered with 20 ml of antacid by HPLC-tandem mass spectrometry method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine.
AID584034Ratio of IC50 for HIV1 reverse transcriptase K103N mutant to IC50 for wild type HIV1 reverse transcriptase2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID523095Half life in healthy human plasma at 750 mg by HPLC-tandem mass spectrometry method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine.
AID584268Inhibition of DNA synthesis in human HepG2 cells assessed as [3H]-thymidine incorporation at up to 10 uM2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID446253Fold resistance, ratio of IC50 for HIV reverse transcriptase with Y181C mutant to IC50 for HIV wild type reverse transcriptase2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID583856Inhibition of human phosphodiesterase 42010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID583842Ratio of IC50 for HIV1 reverse transcriptase Y181I, Y188L mutant to IC50 for wild type HIV1 reverse transcriptase2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID583852Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.005 multiplicities of infection after 6 days2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID1163233Antiviral activity against HIV1 infected in human TZM-bl cells assessed as viral inhibition pre-incubated for 30 mins prior to infection measured after 48 hrs by2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID584044Ratio of IC50 for HIV1 reverse transcriptase L234I mutant to IC50 for wild type HIV1 reverse transcriptase2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584057Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase E233V mutant infected in human HeLaP4 cells assessed as inhibition of viral replication after 5 days by beta-galactosidase reporter assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID446249Clearance in rat at 2 mg/kg, iv2009Bioorganic & medicinal chemistry letters, Oct-15, Volume: 19, Issue:20
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.
AID584036Ratio of IC50 for HIV1 reverse transcriptase V108I mutant to IC50 for wild type HIV1 reverse transcriptase2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584045Ratio of IC50 for HIV1 reverse transcriptase P236L mutant to IC50 for wild type HIV1 reverse transcriptase2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584067Ratio of EC50 for wild type HIV1 NL4-3 to EC50 for HIV1 NL4-3 harboring reverse transcriptase Y181C mutant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584071Ratio of EC50 for wild type HIV1 NL4-3 to EC50 for HIV1 NL4-3 harboring reverse transcriptase F227L mutant2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID584050Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase V108I mutant infected in human HeLaP4 cells assessed as inhibition of viral replication after 5 days by beta-galactosidase reporter assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (11.43)29.6817
2010's28 (80.00)24.3611
2020's3 (8.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.89 (24.57)
Research Supply Index3.93 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials14 (38.89%)5.53%
Reviews4 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (50.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]